Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, announced that it has secured a EUR 5.7 million grant under the France 2030 programme, via the “Biotherapies and Bioproduction of Innovative Therapies” call for projects (AAP), operated by Bpifrance on behalf of the French Government.

The non-dilutive funding will support Phase 2 clinical trials, in France and Europe, of the Company’s lead asset, IGX12. IGX12 is a first-in-class potentiating monoclonal antibody developed to enhance the potency and efficacy of follicle stimulating hormone (FSH), a critical hormone involved in female and male gametogenesis.

Florent Ferré, Chief Executive Officer of Igyxos Biotherapeutics, said, “This funding marks another important new milestone in the clinical development of our innovative approach to treating infertility. Unlike current IVF treatment regimes, our approach addresses both female and male infertility. Male infertilityaccounts for nearly half of all infertility cases and currently has no approved treatment. Our goal is to advance IGX12 through Phase 2 clinical trials in both men and women, with the long term ambition of bringing to market a new therapeutic option for the millions of couples facing fertility challenges around the world.”

In the fourth quarter of 2025, Igyxos expects the latest results from its Phase 1 clinical trial in healthy volunteers. Interim results have demonstrated good safety and tolerability of IGX12 both in men and women.